176 related articles for article (PubMed ID: 28855212)
21. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
22. Spindle assembly checkpoint gene BUB1B is essential in breast cancer cell survival.
Koyuncu D; Sharma U; Goka ET; Lippman ME
Breast Cancer Res Treat; 2021 Jan; 185(2):331-341. PubMed ID: 33130993
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a new human glioblastoma multiforme cell line (WJ1) and its partial characterization.
Wang J; Wang X; Jiang S; Lin P; Zhang J; Wu Y; Xiong Z; Ren JJ; Yang H
Cell Mol Neurobiol; 2007 Nov; 27(7):831-43. PubMed ID: 17703357
[TBL] [Abstract][Full Text] [Related]
24. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Raymond E; Fabbro M; Boige V; Rixe O; Frenay M; Vassal G; Faivre S; Sicard E; Germa C; Rodier JM; Vernillet L; Armand JP
Ann Oncol; 2003 Apr; 14(4):603-14. PubMed ID: 12649109
[TBL] [Abstract][Full Text] [Related]
25. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
[TBL] [Abstract][Full Text] [Related]
26. In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma.
Sa JK; Yoon Y; Kim M; Kim Y; Cho HJ; Lee JK; Kim GS; Han S; Kim WJ; Shin YJ; Joo KM; Paddison PJ; Ishitani T; Lee J; Nam DH
Oncotarget; 2015 Aug; 6(24):20145-59. PubMed ID: 26023737
[TBL] [Abstract][Full Text] [Related]
27. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
28. Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme.
Musumeci G; Magro G; Cardile V; Coco M; Marzagalli R; Castrogiovanni P; Imbesi R; Graziano AC; Barone F; Di Rosa M; Castorina S; Castorina A
Cell Tissue Res; 2015 Oct; 362(1):45-60. PubMed ID: 25948484
[TBL] [Abstract][Full Text] [Related]
29. Long-term exposure to irinotecan reduces cell migration in glioma cells.
Al-Ghafari AB; Punjaruk W; Storer LC; Carrier DJ; Hussein D; Coyle B; Kerr ID
J Neurooncol; 2016 May; 127(3):455-62. PubMed ID: 26830091
[TBL] [Abstract][Full Text] [Related]
30. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
[TBL] [Abstract][Full Text] [Related]
31. Targeting the AKT pathway in glioblastoma.
McDowell KA; Riggins GJ; Gallia GL
Curr Pharm Des; 2011; 17(23):2411-20. PubMed ID: 21827416
[TBL] [Abstract][Full Text] [Related]
32. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
33. Elimination of cancer stem-like side population in human glioblastoma cells accompanied with stemness gene suppression by Korean herbal recipe MSC500.
Yao CJ; Han TY; Shih PH; Yi TY; Lai IC; Chang KH; Lai TY; Chang CL; Lai GM
Integr Cancer Ther; 2014 Nov; 13(6):541-54. PubMed ID: 25359730
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
35. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
[TBL] [Abstract][Full Text] [Related]
36. BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability.
Tang X; Guo M; Ding P; Deng Z; Ke M; Yuan Y; Zhou Y; Lin Z; Li M; Gu C; Gu X; Yang Y
Signal Transduct Target Ther; 2021 Oct; 6(1):361. PubMed ID: 34620840
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma.
Dong S; Huang F; Zhang H; Chen Q
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30765611
[TBL] [Abstract][Full Text] [Related]
38. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
39. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
40. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
